U.S. biotech stocks win back investors in big July run
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/27/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Baird Incrementally Positive on Biogen (BIIB) Nusinersen Data; PT to $284
August 1, 2016 3:16 PM EDTBaird analyst Brian Skorney bumped his price target on Biogen (NASDAQ: BIIB) to $284.00 (from $268.00) but lefts his Neutral rating, saying they are incrementally positive on nusinersen interim Phase 3 results.
Skorney commented, "Results are in, earlier than expected, and nusinersen appears to... More
